Market Overview

UPDATE: Jefferies Raises PT on Celldex Therapeutics on Encouraging Pipeline Outlook

Share:

In a report published Friday, Jefferies reiterated its Buy rating on Celldex Therapeutics (NASDAQ: CLDX), and raised its price target from $9.00 to $15.00.

Jefferies noted, “CLDX provided an encouraging overall pipeline outlook including a risk-mitigated CDX-011 registrational strategy, and favorable rindopepimut and CDX-1135 updates. We believe CLDX represents a compelling biotech play with 2 PIII and 3 PI/II candidates providing multiple shots on goal. Our new $15 PT assumes CLDX will develop/market CDX-011 on its own, booking all U.S. sales (v royalties from a partnership previously).”

Celldex Therapeutics closed on Thursday at $10.49.

Latest Ratings for CLDX

DateFirmActionFromTo
Apr 2018DowngradesOverweightNeutral
Apr 2018MaintainsNeutralNeutral
Mar 2018MaintainsMarket PerformMarket Perform

View More Analyst Ratings for CLDX
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (CLDX)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
ELMDDougherty & Co.Initiates Coverage On12.0
MRNSCantor FitzgeraldAssumes7.0
MNRLCapital One FinancialInitiates Coverage On23.0
SONVertical GroupUpgrades
UNPMorgan StanleyMaintains136.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

UPDATE: Jefferies Raises PT on WuXi PharmaTech on Strong 2013 EPS

Mexico ETF Rises After Surprise Rate Cut